T. Crockett
Founder at KalVista Pharmaceuticals Ltd.
Net worth: 3 M $ as of 2024-03-30
Profile
T.
Andrew Crockett is the founder of KalVista Pharmaceuticals Ltd.
(founded in 2011) where he holds the title of Chief Executive Officer & Director.
He is also the founder of KalVista Pharmaceuticals, Inc. (founded in 2004) where he held the title of Chief Executive Officer & Director until 2024.
Currently, Mr. Crockett is a Director at Vantia Ltd.
since 2010.
In the past, he worked as Vice President-Business Development at ZARS Pharma, Inc. Mr. Crockett's education includes an undergraduate degree from the University of Utah, an MBA from The Wharton School of the University of Pennsylvania, and an undergraduate degree from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-19 | 211,203 ( 0.50% ) | 3 M $ | 2024-03-30 |
T. Crockett active positions
| Companies | Position | Start |
|---|---|---|
Vantia Ltd.
 Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Director/Board Member | 2010-03-31 |
KalVista Pharmaceuticals Ltd.
 KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Founder | 2010-12-31 |
Former positions of T. Crockett
| Companies | Position | End |
|---|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Founder | 2024-03-05 |
ZARS Pharma, Inc.
 ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Corporate Officer/Principal | - |
Training of T. Crockett
| University of Utah | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Harvard Business School | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| KALVISTA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Health Technology |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Commercial Services |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- T. Crockett
